Management of end-stage liver disease in HIV/hepatitis C virus co-infection

Current Opinion in HIV and AIDS

Volumn 6, Issue 6, 2011, Pages 527-533

  Spengler, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

ascites; hepatic encephalopathy; HIV hepatitis C virus co infection; liver cirrhosis; portal hypertension

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; PENTOXIFYLLINE; PROPRANOLOL; RIFAXIMIN; SPIRONOLACTONE; TERLIPRESSIN;

ASCITES; BACTERIAL PERITONITIS; DISEASE COURSE; ELASTOGRAPHY; END STAGE LIVER DISEASE; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATORENAL SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPONATREMIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MIXED INFECTION; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SODIUM RESTRICTION; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT INDICATION; TREATMENT OUTCOME; UPPER GASTROINTESTINAL BLEEDING; VIRUS TRANSMISSION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; COINFECTION; END STAGE LIVER DISEASE; HEPACIVIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC;

EID: 80054998413     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32834bc691     Document Type: Review

References (55)

1. Rosenthal E, Salmon-Céron D, Lewden C, et al., and the Mortavic /Mortalité2005 Study Group. Liver-related deaths in HIv-infected patients between 1995 and 2005 in the French GERMIvIC joint study group network (Mortavic 2005 study in collaboration with the Mortalité2005 survey, ANRS EN19. HIv Med 2009; 10:282-289.
2. Pineda JA, Aguilar-Guisado M, Rivero A, et al., for the Grupo para Estudio de las Hepatitis viricas (Hepavir) de la Sociedad Andaluza de Enfermidades Infecciosas. Natural history of compensated hepatitis C virus-related cirrhosis in HIv-infected patients. Clin Infect Dis 2009; 49:1274-1282.
3. Tuma P, Jarrin I, del Amo J, et al. Survival of HIv-infected patients with compensated Liver cirrhosis. AIDS 2010; 24:745-753.
4. López-Diéguez M, Montes ML, Pascual-Pareja JF, et al., GESIDA 37/03- FIPSE 36465/03-NEAT IG5 Study Group. The natural history of Liver cirrhosis in HIv-hepatitis C virus-coinfected patients. AIDS 2011; 25:899-904.
5. Reiberger T, Ferlitsch A, 'Sieghart W, et al. HIv-HCv co-infected patients with low CD4' cell nadirs are at risk for faster fibrosis progression and portal hypertension. J viral Hepat 2010; 17:400-409.
6. Quirishi N, Kreuzberg C, Lüchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIv and hepatitis C co-infection. Lancet 2003; 362:1708-1713. (Pubitemid 37468321)
7. Thorpe J, Saeed S, Moodie EEM. Klein MB, for the Canadian Co-infection Cohort Study (CTN222). Antiretroviral treatment interruption leads to progression of Liver fibrosis in HIv-hepatitis C virus co-infection. AIDS 2011; 25:967-975.
8. Berenguer J, Alvarez-Pellicer J, Marín PM, et al., and The GESIDA 3603/5607 Study Group. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50:407-413.
9. Meynard J-J, Lacombe K, Poirier J-M, et al. Influence of Liver fibrosis stage on plasma levels of efavirenz in HIv-infected patients with chronic hepatitis B or C. J Antimicrob Cheomther 2009; 63:579-584.
10. Dominguez S, Ghosn J, Peytavin G, et al. Impact of hepatitis C and Liver fibrosis on antiretroviral plasma drug concentrations in HIv-HCv co-infected patients: the HEPADOSE study. J Antimicrob Chemother 2010; 65:2445-2449.
11. Murillas J, Rimola A, Laguno M, et al., and the ESLD-HIv Working Group Investigators. The model for end-stage Liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with endstage Liver disease: a prospective cohort study. Liver Transpl 2009; 15:1133-1141.
12. Subramanian A, Sulkowski M, Barin B, et al. MELD score is an important predictor of pretransplantation mortality in HIv-infected Liver transplant candidates. Gastroenterology 2010; 138:159-164.
13. Singal AG, Thomassen Lv, Gretch DR, Shuhart MC. Use of the AST to platelet ratio index in HCv/HIv co-infected patients. Aliment Pharmacol Ther 2011; 33:566-577.
14. Schiavon LL, Narciso-Schiavon JL, Carvalho-Filho, et al. Impact of CD4' T-cell count on the performance of noninvasive fibrosis markers in HIv-HCv patients. Aliment Pharmacol Ther 2011; 33:1173-1174.
15. Bottero J, Lacombe K, Guéchot J, et al. Performance of 11 biomarkers for Liver fibrosis assessment in HIv/HB co-infected patients. J Hepatol 2009; 50: 1074-1083.
16. de Lédhingen v, vergniol J. Transient elastography (Fibroscan).Gastroenterol Clin Bio 2008; 32:58-67.
17. Grünhage F, Wasmuth JC, Herkenrath S, et al. Transient elastography discloses identical distribution of Liver fibrosis in chronic hepatitis C between HIv-negative and HIv-positive patients on HAART. Eur J Med Res 2010; 15:139-144.
18. Pineda J, Recío E, Camacho A, et al., for the Grupo Andaluz de Hepatitis virica (HEPAvIR) de la Sociedad de Enfermedades Infecciosas (SAEI). Liver stiffness as a predictor of esophageal varices requiring therapy in HIv/ hepatitis C virus-coinfected patients with cirrhosis. J Acquir Immune Defic Syndr 2009; 51:445-449.
19. D'Arminio Montforte A, Cozzi-Lepri A, Castagna A, et al., for the ICONA Foundation Study Group. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIv and hepatitis C virus with and without Liver cirrhosis. Clin Infect Dis 2009; 49:612-622.
20. Tripathi D, Ferguson JW, Kochar N, et al. Randomized controlled trial of Carvedilol versus variceal band ligation for the prevention of the first variceal bleeding. Hepatology 2009; 50:825-833.
21. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, et al. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010:CD002907.
22. De Franchis R, on behalf of the Braveno v faculty. Revising consensus in portal hypertension: report of the Baveno v consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53:762-768.
23. García-Pagán JC, Caca K, Bureau C, et al., Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Co-operative Study Group. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362:2370-2379.
24. Funakoshi N, Ségalas-Largey F, Duny Y, et al. Benefit of combination b-blocker and endoscopic treatment to prevent variceal rebleeding: a meta-analysis. World J Gastroenterol 2010; 16:5982-5992.
25. Angeli P, Fasolato S, Mazza E, et al. Combined versus sequential diuretic treatment of ascites in nonazotemic patients with cirrhosis: results of an open randomized clinical trial. Gut 2010; 59:98-104.
26. Bernardi M. Optimum use of diuretics in managing ascites in patients with cirrhosis. Gut 2010; 59:10-11.
27. Moore KP, Wong F, Gines̀ P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38:258-266. (Pubitemid 36775818)
28. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome. J Hepatol 2010; 53:397-417.
29. Salerno F, Cammà C, Enea M, et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133:825-834 (Pubitemid 47374134)
30. Singh v, Dheerendra PC, Singh B, et al. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol 2008; 103:1399-1405. (Pubitemid 351813906)
31. Krag A, Møller S, Henriksen JH, et al. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 20072007; 46:1863-1871.
32. Wong F, Gines P, Watson H, et al. Effects of a selective vasopressin v2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol 2010; 53:283-290.
33. Wong F, Bernardi M, Horsmans Y, et al. Effects of satavaptan, an oral vasopressin v2 receptor antagonist, on management of ascites and morbidity in Liver cirrhosis in a long-term, placebo-controlled study. J Hepatol 2009; 50 (Suppl 1):S42-S43.
34. Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010; 51:576-584.
35. Senzolo M, Cholongitas E, Burra P, et al. b-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int 2009; 29:1189-1193.
36. SerstéT, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010; 52:1017-1022.
37. Lebrec D, Thabut D, Oberti F, et al., for the Pentocir Group. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010; 138:1755-1762.
38. Fernández J, Navasa M, Gómez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35:140-148. (Pubitemid 34032554)
39. Sort P, Navasa M, Arroyo v, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341:403-409. (Pubitemid 29362513)
40. Ginés P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12:716-724. (Pubitemid 20349256)
41. Fernández J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133:818-824. (Pubitemid 47374144)
42. Cohen MJ, Sahar T, Benenson S, et al. Antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleeding. Cochrane Database Syst Rev 2009: CD00479.
43. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362:1071-1081.
44. Sidhu SS, Goyal O, Mishra BP, et al. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011; 106:307-316.
45. Ragni Mv, Eghttesad B, Schlesinger KW, et al. Pretransplant survival is shorter in HIv-positive than HIv-negative subjects with end-stage Liver disease. Liver Transplant 2005; 11:1425-1430. (Pubitemid 43071593)
46. Sugawara Y, Tamura S, Kokudo N. Liver transplantation in HCv/HIv positive patients. World J Gastrointest Surg 2011; 3:21-28.
47. Ragni Mv, Belle SH, Im K, et al. Survival of human immunodeficiency virusinfected Liver transplant recipients. J Infect Dis 2003; 188:1412-1420. (Pubitemid 37523925)
48. Neff GW, Bonham A, Tzakis AG, et al. Orthotopic Liver transplantation in patients with human immunodeficiency virus and endstage Liver disease. Liver Transpl 2003; 9:239-247. (Pubitemid 36322325)
49. de vera ME, Dvorchik I, Tom K, et al. Survival of Liver transplant patients coinfected with HIv and HCv is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6:2983-2993.
50. Schreibman I, Gaynor JJ, Jayaweera D, et al. Outcomes after orthotopic Liver transplantation in 15 HIv-infected patients. Transplantation 2007; 84:697-705. (Pubitemid 47480654)
51. Miro J, Montejo M, Castells L, et al. Prognostic factors of mortality in HCv/HIv coinfected Liver transplant recipients from the FIPSE OLT-HIv-05- GESIDA 45-05 Cohort Study (2002-2006). 15th CROI Meeting, Boston, MA; 2008.p. 177.
52. Mindikoglu AL, Regev A, Magder LS. Impact of human immunodeficiency virus on survival after Liver transplantation: analysis of United Network for Organ Sharing database. Transplantation 2008; 85:359-368. (Pubitemid 351322759)
53. Duclos-vallee JC, Feray C, Sebagh M, et al. Survival and recurrence of hepatitis C after Liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47:407-417. (Pubitemid 351280708)
54. Wojcik K, vogel M, voigt E, et al. Antiviral therapy for hepatitis C virus recurrence after Liver transplantation in HIv-infected patients: outcome in the Bonn cohort. AIDS 2007; 21:1363-1365. (Pubitemid 46883493)
55. Castells L, Esteban JI, Bilbao I, et al. Early antiviral treatment of hepatitis C virus recurrence after Liver transplantation in HIv-infected patients. Antivir Ther 2006; 11:1061-1070. (Pubitemid 44955182)